

Change in FEV₁ and FENO Measurements as Predictors of Future Asthma Outcomes in Children



Shona Fielding, PhD; Marielle Pijnenburg, PhD; Johan C. de Jongste, PhD; Katharine C. Pike, PhD; Graham Roberts, DM; Helen Petsky, PhD; Anne B. Chang, PhD; Maria Fritsch, MD; Thomas Frischer, MD; Stanley Szeffler, MD; Peter Gergen, MD; Françoise Vermeulen, MD; Robin Vael; and Steve Turner, MD

BACKGROUND: Repeated measurements of spirometry and fractional exhaled nitric oxide (FENO) are recommended as part of the management of childhood asthma, but the evidence base for such recommendations is small. We tested the hypothesis that reducing spirometric indices or increasing FENO will predict poor future asthma outcomes.

METHODS: A one-stage individual patient data meta-analysis used data from seven randomized controlled trials in which FENO was used to guide asthma treatment; spirometric indices were also measured. Change in %FEV₁ and % change in FENO between baseline and 3 months were related to having poor asthma control and to having an asthma exacerbation between 3 and 6 months after baseline.

RESULTS: Data were available from 1,112 children (mean age, 12.6 years; mean %FEV₁, 94%). A 10% reduction in %FEV₁ between baseline and 3 months was associated with 28% increased odds for asthma exacerbation (95% CI, 3-58) and with 21% increased odds for having poor asthma control (95% CI, 0-45) 6 months after baseline. A 50% increase in FENO between baseline and 3 months was associated with 11% increase in odds for poor asthma control 6 months after baseline (95% CI, 0-16). Baseline FENO and %FEV₁ were not related to asthma outcomes at 3 months.

CONCLUSIONS: Repeated measurements of %FEV₁ that are typically within the “normal” range add to clinical risk assessment of future asthma outcomes in children. The role of repeated FENO measurements is less certain because large changes were associated with small changes in outcome risk.

CHEST 2019; 155(2):331-341

KEY WORDS: asthma; child; monitoring; nitric oxide; spirometry

ABBREVIATIONS: ERS = European Respiratory Society; FEF₂₅₋₇₅ = forced expiratory flow at 25-75% of FVC; FENO = fractional exhaled nitric oxide; GLI = Global Lung Initiative; ICS = inhaled corticosteroid; IPD = individual patient data; IQR = interquartile range; LTRA = leukotriene receptor antagonist; NHANES = National Health and Nutrition Examination Survey; RCT = randomized controlled trial

AFFILIATIONS: From the Medical Statistics Team (Dr Fielding), Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland; Department of Paediatric Respiratory Medicine and Allergology (Drs Pijnenburg and de Jongste), Erasmus MC, Sophia Children's Hospital, Rotterdam, the Netherlands; Clinical and Experimental Science Academic Unit (Drs Pike and Roberts), University of Southampton, Southampton, England; Respiratory Critical Care and Anaesthesia Group (Dr Pike), Institute of Child Health, University College London, London, England; Department of Respiratory and Sleep Medicine (Drs Petsky and Chang), Lady Cilento Children's Hospital, Queensland University of Technology, Brisbane, Australia; Child Health Division (Dr Chang), Menzies School of Health Research, Charles Darwin University, Darwin, Australia; Department of General Paediatrics (Drs Fritsch and Frischer), University

Children's Hospital, Vienna, Austria; Breathing Institute (Dr Szeffler), Children's Hospital Colorado, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO; National Institute of Allergy and Infectious Diseases (Dr Gergen), Bethesda, MD; Pediatric Department (Dr Vermeulen), Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; Department of Paediatrics (Mr Vael), Antwerp University Hospital, Antwerp, Belgium; and the Department of Child Health (Dr Turner), University of Aberdeen, Royal Aberdeen Children's Hospital, Aberdeen, Scotland.

FUNDING/SUPPORT: The authors have reported to CHEST that no funding was received for this study.

CORRESPONDENCE TO: Steve Turner, MD, Department of Child Health, University of Aberdeen, Royal Aberdeen Children's Hospital, Foresterhill, Aberdeen, Scotland, AB25 2ZG; e-mail: s.w.turner@abdn.ac.uk

Copyright © 2018 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

DOI: <https://doi.org/10.1016/j.chest.2018.10.009>

Asthma is a common condition affecting 1 million children in the United Kingdom¹ and 6 million in the United States.² Guidelines recommend that objective markers of respiratory function (eg, FEV₁) and airway inflammation (eg, fractional exhaled nitric oxide [FENO]) may be used in conjunction with symptoms to guide asthma preventive treatment in children. These recommendations differ between guidelines, however, and none gives clinicians advice how to interpret changes in spirometry when values fall within the normal range, yet FEV₁ (the most commonly used spirometric index) is usually within normal limits.³

One guideline recommends that lung function should be “monitored and recorded” only in children >12 years of age.⁴ Two guidelines recommend that FEV₁ may be useful for monitoring of asthma for children aged between ages 5 and 7 years.^{5,6} A fourth guideline⁷ recommends that lung function should be measured 3 to 6 months after treatment is started and “periodically” thereafter, and that %FEV₁ <60% identifies a patient at risk for future asthma exacerbations. A fifth guideline⁸ recommends that lung function should be measured every 1 to 2 years (more frequently when symptoms are poorly controlled) and suggests that treatment might be stepped up if %FEV₁ is <80% or <60%. Some guidelines

suggest that a 20% drop in FEV₁ relative to personal best identifies an individual at risk for future asthma exacerbations.^{5,7}

Although FENO is recommended by the US Food and Drug Administration for monitoring asthma,⁹ there is no consensus on how results should be interpreted; one international guideline states that a change in FENO of 10 ppb or 20% may be clinically relevant.¹⁰

To understand the relationship between change in spirometry and FENO and asthma outcomes, we obtained individual patient data (IPD) from seven FENO randomized controlled trials (RCTs) in which details of spirometry, FENO, asthma control, and the occurrence of asthma exacerbations were collected longitudinally.¹¹⁻¹⁷ Our primary hypothesis was that falling spirometric indices (with %FEV₁ as the primary index) and/or rising FENO between randomization and 3-month follow-up will be associated with increased risk for asthma being uncontrolled and for an asthma exacerbation between 3- and 6-month follow-up. The secondary hypothesis was that, at baseline, low spirometric indices and high FENO will be associated with increased risk for asthma being uncontrolled and for an asthma exacerbation between baseline and 3-month follow-up.

Methods

Study Design

Authors of published RCTs in which measurements of FENO were used to guide asthma treatment in children¹⁸ were invited to provide anonymized data for IPD.¹⁹ The outcomes were asthma exacerbation (defined as a prescription of prednisolone during the follow-up period and derived using data provided by study authors) and poor asthma control (defined by per trial protocol by symptom score, and including FEV₁ cutoff values in some trials^{11,12,16} but not including an asthma exacerbation). **e-Appendix 1** provides definitions of being uncontrolled. For all RCTs, prescribing oral corticosteroids for asthma exacerbations was at the discretion of the attending doctor. The explanatory variables between baseline and 3-month follow-up were absolute change and %change in FENO and absolute change in percentage of predicted (%) spirometry; the analysis of change in % spirometry and % change in FENO included the corresponding baseline measurement. The relationship between outcomes and the following explanatory variables at baseline were sought: FENO and %FEV₁, %FEV₁/FVC, forced expiratory flow at 25% to 75% of FVC (%FEF₂₅₋₇₅), and %FVC. **Figure 1** shows which physiological measurements (and changes) were linked to later asthma outcomes in this study. Additional covariates collected at baseline and included in the models were: age, sex, height, weight, ethnicity, trial arm, dose of inhaled corticosteroid (ICS, as daily budesonide equivalent dose), prescribed long-acting beta agonist (LABA) or not, prescribed leukotriene receptor agonist (LTRA) or not, asthma control, and treatment compliance. For each follow up visit, the following variables were collected: FENO, FEV₁, height, dose of ICS, asthma control, and asthma exacerbation since the

previous visit. The focus of this study was follow-up at 3 and 6 months because these are typically used in asthma clinics; for trials in which there was no 3- or 6-month assessment, the assessment closest to these time points was used. In all but two studies,^{14,15} absolute spirometry data were available and expressed as percentage of predicted to the Global Lung Initiative (GLI) standard²⁰; where absolute data were not available, the % predicted value provided by the local team was used for analysis. Although % FEV₁ was the primary spirometric index of interest, %FEV₁/FVC, %FEF₂₅₋₇₅, and %FVC were also considered to determine which index had the greatest precision for future outcomes. For completeness, FEV₁ was also expressed as z score and centile (standardized to the GLI standard²⁰). Additionally, as a sensitivity analysis, %FEV₁ was derived using National Asthma Education and Prevention Program (NHANES) III standard²¹ to determine whether any relationship between %FEV₁ and later outcome was dependent on the standard used. BMI was derived and International Obesity Task Force weight categories created.²² In each trial, FENO was measured in accordance with the 2005 guideline.²³ Ethical approval was obtained for each individual study but was not required for the IPD.

Individual Patient Data Analysis

Demographic and baseline characteristics were obtained for each study. A one-stage IPD meta-analysis was undertaken using the *melogit* command in STATA with study included as a random effect. All models were adjusted for the baseline variables of age, sex, LABA, LTRA, asthma control, ICS dose, arm of trial and, where relevant, baseline FENO or baseline FEV₁. A one-stage approach was used rather than a two-stage approach because some of the studies




Figure 1 – A diagram showing how different physiological measurements were linked to later asthma outcomes in the study’s analyses. The analyses used data collected at recruitment to seven clinical trials and at follow-up assessments 3 and 6 months after recruitment. ^aAlthough %FEV₁ was the primary spirometric index, the following were also considered: %FEV₁/FVC, %FEF₂₅₋₇₅, and %FVC. FENO = fractional exhaled nitric oxide.

had low event counts (few asthma exacerbations), and adoption of one-stage in this instance is recommended by Burke et al.²⁴ Sensitivity analyses considered separately outcomes for individuals in FENO

intervention and standard care arms of the trials and also excluded data from trials in which %FEV₁ was used to guide treatment decisions.^{11,12,16} STATA, version 14, was used for analysis.

Results

Study Subjects

Data from seven pediatric RCTs were analyzed (Table 1)¹¹⁻¹⁷; data from an eighth RCT could not be obtained.²⁵ Details of population inclusion and exclusion criteria are presented in e-Appendix 1. The IPD included data on 1,112 participants. In two studies,^{14,17} spirometry was measured at baseline and at 12 months only, and change in %FEV₁ between baseline and 3 months could not be calculated. There was a predominance of male participants (58%) and mean (SD) age was 12.6 (3.1) years (Table 2). For individual RCTs, median values of FENO varied between 18 and 34 ppb with an overall median (interquartile range [IQR]) of 22 ppb (12, 43). Mean %FEV₁ values at baseline varied between 89% and 98% predicted with an overall mean (SD) of 94% (18). Details of mean FEV₁ z scores and centile are presented in e-Table 1. The Pearson correlation coefficient between FENO and %FEV₁ at baseline was -0.184 (n = 1,025, P < .001) and between % change in FENO (baseline to 3 months) and change in %FEV₁ (baseline to 3 months) was -0.127 (n = 759, P < .001). Overall, 7% of participants had an asthma

exacerbation during the first 3 months and 12% in the second 3 months, whereas 27% were uncontrolled at baseline, 25% at 3 months, and 23% at 6 months, (Table 3). An asthma exacerbation occurred between baseline and 3 months in 47 (7%) of the 718 participants with controlled symptoms at baseline and in 27 (12%) of 230 with uncontrolled symptoms at baseline.

Relationship Between Change in Spirometry and Percentage Change in FENO Between Baseline and 3 Months and Outcomes Between 3 and 6 Months

Between baseline and 3 months, the mean (SD) change in %FEV₁ was -0.17 (10.4), the median absolute change in FENO was 0.6 ppb (IQR, -7.9, 12.2), and the median % change in FENO was 3.7% (IQR, -30.4, 66.7). A fall in % FEV₁ was related to increased odds of an asthma exacerbation over the following 3 months (eg, a reduction of 10% FEV₁ between baseline and 3 months was associated with increased OR for future exacerbation between 3 and 6 months of 1.3 [1.0, 1.6], P = .027) and loss of future asthma control (eg, a reduction of 10% FEV₁ was associated with increased OR for uncontrolled asthma 1.2 [96% CI, 1.0-1.4], P = .046) (Table 4). A reduction of 10% FVC was also

TABLE 1] Details of the Randomized Controlled Trials Included in This Individual Patient Data Analysis

Study	Mean Age, y		Intervals at Follow-up After Baseline When FENO Was Measured (mo) ^a	Intervals at Follow-up After Baseline When Spirometry Was Measured (mo) ^a	Were Absolute Spirometry Data Available?	Which Spirometric Indices Were Available?	Was There a Run-in Period?	Was Atopy an Inclusion Criteria?	What Measure of Asthma Control Was Used?
	FENO Arm	Control Arm							
Fritsch et al ¹¹	11.3	12.1	0, 1.5, 3, 4.5, 6	0, 1.5, 3, 4.5, 6	Yes	FEV ₁ , FVC	Yes	Yes	Unvalidated symptom diary
Peirsman et al ¹²	10.6	10.7	0, 3, 6, 9, 12	0, 3, 6, 9, 12	Yes	FEV ₁	No	Yes	First 4 (of 7) questions on C-ACT ^b
Petsky et al ¹³	9.9	10.1	0, 1, 2, 3, 4, 6, 8, 10, 12	0, 1, 2, 3, 4, 6, 8, 10, 12	Yes	FEV ₁ , FEF ₂₅₋₇₅ , FVC	Yes	No	Validated symptom diary
Pijnenburg et al ¹⁴	11.9	12.6	0, 3, 6, 9, 12	0, 12	No	FEV ₁ , FEF ₅₀ , FVC	Yes	Yes	Validated symptom diary
Pike et al ¹⁵	10.5	11.4	0, 2, 4, 6, 7, 10, 12	0, 2, 4, 6, 7, 10, 12	No	FEV ₁ , FVC	No	No	Modified validated symptom diary ^b
Szefer et al ¹⁶	14.4	14.4	0, 1.5, 3.2, 5, 7, 8.5, 10.5	0, 1.5, 3.2, 5, 7, 8.5, 10.5	Yes	FEV ₁ , FEF ₂₅₋₇₅ , FVC	Yes	No	ACT ^c plus FEV ₁
Voorend-van Bergen et al ¹⁷	10.3	10.2	0, 4, 8, 12	0, 12	Yes	FEV ₁ , FEF ₇₅ , FVC	Yes	Yes	ACT and C-ACT

ACT = asthma control test, C-ACT = Childhood Asthma Control Test; FEF₂₅₋₇₅, forced expiratory flow at 25% to 75% of FVC; FENO = fractional exhaled nitric oxide.

^aZero corresponds to baseline.

^bReliever medication use and FEV₁.

^cFEV₁ alone were used in the treatment algorithm for both arms of the RCT but were not used to define being uncontrolled in this study.

TABLE 2] Characteristic of Study Participants at the Baseline Visit in Each Study

Characteristic	Fritsch et al ¹¹	Peirsman et al ¹²	Petsky et al ¹³	Pijnenburg et al ¹⁴	Pike et al ¹⁵	Szeffler et al ¹⁶	Voorend-van Bergen et al ¹⁷	All Populations Combined
Total No. participants	47	99	63	86	90	546	181	1,112
Men, % (No.)	60 (28)	67 (66)	49 (31)	65 (56)	57 (51)	53 (288)	68 (123)	58 (643)
Age								
Mean (SD)	11.5 (3.1)	10.7 (2.1)	10.0 (3.2)	12.3 (2.8)	10.9 (2.6)	14.4 (2.1)	10.2 (3.0)	12.6 (3.1)
Range	6–17	5–14	4–16	6–18	5–16	12–19	4–18	4–19
Trial arm								
Standard	25	50	32	46	46	270	92	561
FENO	22	49	31	40	44	276	89	551
FENO								
No. observations	46	49	61	86	90	546	179	1,057
Median, ppb	33.9	31.3	25.6	32	25.5	20.1	18.2	21.9
IQR, ppb	(18.6, 58.6)	(14, 69)	(12.2, 47.5)	(16.6, 52.5)	(10, 48)	(11.2, 40.6)	(10.2, 30.4)	(11.6, 43.0)
% predicted FEV ₁								
No. observations	47	98	54	86	90	546	157	1,078
Mean (SD)	93.5 (15.7)	91.4 (15.7)	90.7 (15.6)	97.5 (17.5)	89.2 (14.3)	90.9 (16.6)	93.8 (13.0)	93.5 (18.1)
% predicted FEV ₁ /FVC								
No. observations	47	0	0	0	0	546	156	749
Mean (SD)	90.1 (10.6)	-	-	-	-	91.3 (9.9)	93.4 (9.4)	91.7 (9.9)
% with positive skin prick test	100	100	38 (24/63)	100	76 (68/90)	88 (467/531)	100	89 (972/1,097)
Mean centile BMI (SD)								
No. observations	47	99	58	86	89	546	181	1,106
Mean (SD)	67.6 (27.0)	52.1 (30.1)	48.5 (32.4)	60.8 (27.3)	64.2 (32.2)	83.1 (23.5)	58.9 (29.9)	70.7 (29.8)

(Continued)

TABLE 2] (Continued)

Characteristic	Fritsch et al ¹¹	Peirsman et al ¹²	Petsky et al ¹³	Pijnenburg et al ¹⁴	Pike et al ¹⁵	Szeffler et al ¹⁶	Voorend-van Bergen et al ¹⁷	All Populations Combined
Obese								
No. observations	47	99	58	85	89	526	181	1,085
% (No.) overweight	28 (13)	12 (12)	16 (9)	14 (12)	25 (22)	28 (145)	20 (36)	23 (249)
% (No.) obese	8 (4)	1 (1)	2 (1)	4 (4)	8 (7)	31 (165)	3 (5)	17 (187)
LTRA treatment prescribed								
No. observations	47	99	58	86	90	546	181	1,107
% (No.) yes	28 (13)	60 (59)	10 (6)	0	51 (46)	15 (80)	13 (23)	21 (227)
LABA treatment prescribed								
No. observations	47	99	58	86	90	546	181	1,107
% (No.) yes	38 (18)	32 (32)	67 (39)	38 (33)	76 (68)	66 (360)	46 (84)	57 (634)
Median dose of inhaled corticosteroids (IQR)	400 (0, 800)	320 (200, 400)	400 (250, 500)	800 (400, 1,000)	800 (400, 1,000)	1000 (400, 2,000)	400 (400, 800)	400 (400, 1,000)
Ethnic group, % (No.)								
No. observations	0	84	20	0	90	526	179	889
White		82 (69)			92 (83)		89 (160)	35 (312)
Hispanic						65 (340)		38 (340)
Other		18 (15)	100 (20)		8 (7)	35 (186)	11 (19)	28 (247)
Asthma control status								
No. observations	47	65	57	77	90	528	181	1,045
Asthma controlled, % (No.)	49 (23)	75 (49)	72 (41)	57 (44)	68 (62)	80 (421)	67 (122)	73 (762)
Asthma not controlled, % (No.)	51 (24)	25 (16)	28 (16)	43 (33)	31 (28)	20 (107)	33 (59)	27 (283)

IQR = interquartile ratio; LABA = long-acting beta agonist; LTRA = leukotriene receptor agonist. See Table 1 legend for expansion of other abbreviations.

TABLE 3] Frequency of Outcomes Between Baseline and 3 Months and Between 3 and 6 Months post baseline

Study	Exacerbation Between Baseline and 3 Mo	Exacerbation Between 3 and 6 Mo	Asthma Not Controlled at 3 Mo	Asthma Not Controlled at 6 Mo
Fritsch et al ¹¹	2 (1/47)	6 (3/47)	54 (25/46)	53 (25/47)
Peirsman et al ¹²	4 (4/99)	0	25 (21/83)	21 (18/86)
Petsky et al ¹³	5 (3/63)	8 (5/63)	NA	NA
Pijnenburg et al ¹⁴	9 (8/86)	8 (7/86)	40 (32/81)	40 (31/78)
Pike et al ¹⁵	17 (15/90)	30 (27/90)	26 (23/90)	32 (29/90)
Szeffler et al ¹⁶	7 (35/522)	15 (78/505)	21 (111/541)	17 (86/513)
Voorend-van Bergen et al ¹⁷	7 (12/181)	7 (12/181)	21 (38/179)	20 (36/178)
Overall	7 (78/1,088)	12 (132/1,071)	25 (250/1,010)	23 (225/992)

Data are presented as No. (%). NA = not available.

associated with increased odds for a future exacerbation (OR, 1.40 [1.04, 1.88], $P = .026$); *e-Table 2*. A 50% increase in F_{ENO} between baseline and 3 months was associated with 11% increased odds of asthma being uncontrolled at 6 months (95% CI, 0-16; $P = .014$) but not odds of an exacerbation between 3 and 6 months (*Table 4*). When both change in %FEV₁ and %change in F_{ENO} were considered in the same model, the OR for asthma being uncontrolled remained significant for F_{ENO} ($P = .036$) but not for %FEV₁ ($P = .061$). Neither change in %FEV₁/FVC or %FEF₂₅₋₇₅ (*e-Table 2*) nor absolute change in F_{ENO} (*Table 4*) were associated with outcomes. The associations between change in %FEV₁ and % change in F_{ENO} did not achieve significance when each trial arm was considered separately (*e-Table 3*). When the RCTs in which %FEV₁ was used to guide treatment were excluded, there was an association between rising F_{ENO} and future asthma exacerbation ($P = .029$), but associations between change in FEV₁ and outcomes were not significant (*e-Table 4*). Among the subset of RCTs in which FEV₁ z score and centile values could be derived, falling z scores were associated with increased odds for both asthma exacerbations and being uncontrolled and falling centile score with being uncontrolled (*e-Table 5*). The results seen with change in % FEV₁ using the GLI standard were also seen when the NHANES III standard was used (*e-Table 6*).

Relationship Between Baseline F_{ENO} and Spirometric Indices and Outcomes at 3Months

Percentage of predicted FEV₁/FVC at baseline (but no other spirometric index) was related to the odds of asthma exacerbation at 3 months during this interval ($P = .016$; *Table 5*). No index of spirometry at baseline was related to having uncontrolled asthma at 3 months. F_{ENO} at baseline was not related to asthma outcomes at

3 months (*Table 5*). *e-Table 6* demonstrates that when FEV₁ was standardized to the NHANES III data, reducing %FEV₁ at baseline was associated with increased odds for future asthma exacerbation ($P = .033$) and a trend for reduced odds for asthma not being controlled in future ($P = .055$). Baseline FEV₁ z score or centile were not related to outcomes (*e-Table 7*).

Discussion

This study sought to understand the relationship between changes in spirometric measurements and F_{ENO} and future asthma outcomes. The first finding was that, independent of all factors that might influence treatment decisions, falling %FEV₁ (even within the range of 80% to 120% commonly considered as “normal”) was associated with increased odds for future asthma exacerbation and having uncontrolled asthma. A second finding was that an absolute change in F_{ENO} (*Table 4*) did not predict outcomes, and only a large rise in % change in F_{ENO} was related to a small increase in the odds for having uncontrolled asthma in the future. We also observed that at baseline, a “one-off” %FEV₁/FVC ratio (but not %FEV₁) was associated with future odds for asthma exacerbation. Together, the results suggest that change in %FEV₁ can be used as part of risk assessment for asthma outcomes. The role of change in F_{ENO} is less clear, and future clinical trials could include % change in F_{ENO} as part of a treatment algorithm for children with asthma.

The individuals whose data contributed to this study were participating in RCTs, and this could mean that the results are not necessarily generalizable for at least two reasons. First, participants in RCTs often have to fulfill specific eligibility criteria, receive more clinical contact than standard care, and often have better outcomes such

TABLE 4] Relationship Between Falling %FEV₁ or Rising % Change in F_{ENO} Over a 3-Mo Period and Odds of Having an Asthma Attack or Uncontrolled Asthma During the Next 3 Mon

Change in Measurement of Respiratory Function	Asthma Outcome	OR per Unit Change in FEV ₁ or F _{ENO} ^a	OR per 5, 10, and 20 Reduction in %FEV ₁ ^b			OR per 20% and 50% Increase in F _{ENO} ^b		OR per 20 and 50 ppb Increase in F _{ENO} ^b	
			%FEV ₁ Reduced by 5	%FEV ₁ Reduced by 10	%FEV ₁ Reduced by 20	20% Increase in F _{ENO}	50% Increase in F _{ENO}	20 ppb Increase in F _{ENO}	50 ppb Increase in F _{ENO}
Change (baseline to 3 mo) in % FEV ₁	≥1 asthma attack between 3 and 6 mo ^c	1.025 (1.003, 1.047), <i>P</i> = .027, n = 716 (5 trials)	1.131 [1.015, 1.258]	1.280 [1.030, 1.583]	1.639 [1.062, 2.506]				
	Asthma uncontrolled at 6 mo	1.019 (1.000, 1.038), <i>P</i> = .046, n = 693 (4 trials)	1.099 [1.000, 1.205]	1.207 [1.000, 1.452]	1.457 [1.000, 2.108]				
% change in F _{ENO} (baseline to 3 mo)	≥1 asthma attack between 3 and 6 mo ^c	1.001 (0.999, 1.003), <i>P</i> = .228, n = 929 (7 trials)				1.020 [0.980, 1.062]	1.051 [0.951, 1.162]		
	Asthma uncontrolled at 6 mo	1.002 (1.000, 1.003), <i>P</i> = .014, n = 897 (6 trials)				1.041 [1.000, 1.062]	1.105 [1.00, 1.162]		
Absolute change in F _{ENO} (baseline to 3 mo), ppb	≥1 asthma attack between 3 and 6 mo ^c	1.004 (0.998, 1.010), <i>P</i> = .197, n = 929 (7 trials)						1.083 [0.961, 1.220]	1.221 [0.905, 1.645]
	Asthma uncontrolled at 6 mo	1.002 (0.997, 1.008), <i>P</i> = .07, n = 897 (6 trials)						1.041 [0.942, 1.173]	1.105 [0.861, 1.489]

Results are from a 1-stage individual patient data analysis. All models adjusted for sex, age, treatment with long-acting beta agonists at baseline, treatment with leukotriene receptor antagonist at baseline, asthma control at baseline, and change in dose of inhaled corticosteroid between baseline and 3 mo. See Table 1 legend for expansion of abbreviations.

^aFor change in %FEV₁, “per unit” means for each percentage change (eg, from 98% to 97% FEV₁); %change in F_{ENO} means for each percent change (eg, from 100 to 101 ppb); and absolute change in F_{ENO} “per unit” means ppb change (eg, from 35 to 36 ppb).

^bOR for outcomes were derived from the OR per unit change; for example, OR for asthma attack after a reduction in %FEV₁ of 5 is 1.025 to the power of 5.

^cThe model also includes asthma attack between baseline and 3 mo. The change in F_{ENO} model included F_{ENO} at baseline; the change in FEV₁ model included FEV₁ at baseline.

TABLE 5] Relationship Between Baseline %FEV₁ or Baseline F_{ENO} and Odds of Asthma Attack or Asthma Being Uncontrolled During the Next 3 Mo

Measurement of Respiratory Function	Asthma Outcome	OR per Unit Reduction in FEV ₁ or Rise in F _{ENO} ³
%FEV ₁ at baseline	≥1 asthma attack between baseline and 3 mo	1.011 (0.997, 1.026), <i>P</i> = .118, n = 973 (7 trials)
	Asthma uncontrolled at 3 mo	0.993 (0.984, 1.001), <i>P</i> = .098, n = 939 (6 trials)
%FEV ₁ /FVC at baseline	≥1 asthma attack between baseline and 3 mo	1.037 (1.007, 1.067), <i>P</i> = .016, n = 706 (3 trials)
	Asthma uncontrolled at 3 mo	0.993 (0.973, 1.012), <i>P</i> = .451, n = 715 (3 trials)
F _{ENO} (ppb) at baseline	≥1 asthma attack between baseline and 3 mo	1.001 (0.995, 1.008), <i>P</i> = .682, n = 966 (7 trials)
	Asthma uncontrolled at 3 mo	1.002 (0.997, 1.007), <i>P</i> = .476, n = 929 (6 trials)

Results are from a 1-stage individual patient data analysis. All models adjusted for sex, age, treatment with long-acting beta agonists at baseline, treatment with leukotriene receptor antagonist at baseline, asthma control at baseline, and change in dose of inhaled corticosteroid between baseline and 3 mo. ³For %FEV₁, “per unit” means for each percentage reduction (eg, from 98% to 97% FEV₁) and for F_{ENO} “per unit” means per part per billion change (eg, from 35 to 36 ppb).

as fewer asthma exacerbations, but these differences are likely to weaken any association between F_{ENO} or %FEV₁ and asthma outcomes by narrowing the phenotype of participants and improving outcomes. Second, the participants in our study had treatment guided by F_{ENO} (and %FEV₁ in three studies); thus, the predictive variables in our study may have affected the outcome (eg, rising F_{ENO} leading to increased ICS resulting in good asthma control). We justify inclusion of data from these trials because, first, F_{ENO} and, in all but one study,¹⁴ %FEV₁, did not differ between trial arms during the RCT; second, if F_{ENO} or %FEV₁ did improve asthma outcomes by protocol-driven treatment changes, this would have weakened any association between F_{ENO} or %FEV₁ and asthma control or asthma exacerbations. Our inclusion of participants in RCTs may therefore have weakened the associations described; in “real life,” change in %FEV₁ and % change in F_{ENO} may have greater precision for outcomes than indicated by our results.

There are some limitations to our study. First, the methodologies of the RCTs were different; in particular, three of the RCT¹⁵⁻¹⁷ intervals between assessments did not include multiples of 3 months. This heterogeneity may have weakened the associations described, assuming that the relationship between F_{ENO} and FEV₁ and outcomes changes over time. Different methods were used to assess asthma control; again, this would weaken and not strengthen the associations described between baseline %FEV₁ or %change in F_{ENO} and being uncontrolled in future. A second limitation is that the range of %FEV₁ values was relatively narrow and the

incidence of asthma exacerbations was relatively low; this could make the relationship between physiological measurement and clinical outcome difficult to detect. Nonetheless, we were still able to observe an association between %FEV₁ and future asthma exacerbations. A third limitation is that we did not have an objective measure of adherence and could not consider how nonadherence may have influenced asthma control and exacerbations; however, this information is not available for most clinicians and thus our study reflects the real world. A fourth limitation is that none of the RCTs included an assessment of short-term variability of pulmonary function, such as PEF variability or bronchodilator response, and we are not able to say how short-term variability in pulmonary function might be related to future asthma outcomes.

The magnitude of the change in OR for an asthma exacerbation or being uncontrolled in future in the context of changing %FEV₁ and F_{ENO} were relatively small, and this is partly because we included RCT participants as previously discussed and partly because the model considered many other factors that might predict poor asthma outcomes (eg, current symptom control, treatment level, current %FEV₁).

In our sensitivity analyses, we excluded the three studies in which %FEV₁ was used to guide treatment; the results seen in the whole population were no longer significant, and this is most likely explained by lack of power. When we split results by trial arm, the significant associations seen between change in %FEV₁ and %change in F_{ENO} for the whole population were also nonsignificant; this is also most likely because of a lack of power in the analysis.

We are not aware of published studies that relate change in spirometry to future asthma outcomes, but there are several studies in which spirometry on a single occasion has been related to subsequent asthma outcomes in children. One study reported an inverse relationship between reduced %FEV₁ and increased risk for asthma exacerbation in the next 12 months.²⁶ Two further studies^{27,28} (data from one²⁷ contributed to the present IPD) reported that reduced FEV₁/FVC ratio was associated with increased risk for future exacerbation.

The 2015 European Respiratory Society Task Force on Monitoring Asthma in Children²⁹ stated that “the meaning of significant changes in FENO in a longitudinal setting is still unclear and needs further attention, and that “the use of ‘personal best’ cut-off points in FENO algorithms requires further investigation.” Our study

findings suggest that a relatively large rise (50%) in FENO over 3 months (independent of treatment and initial symptoms) may be a useful predictor of having uncontrolled asthma in future but not for asthma exacerbations. Additionally, our results suggest that a single FENO value and absolute change in FENO over time are unlikely to be clinically useful.

In summary, our results suggest that %FEV₁ within the “normal” range over 3-month periods could assist with risk assessment in childhood asthma. These findings now need replicating elsewhere. A fall in %FEV₁ and a rise in FENO should prompt an evaluation of medication adherence, inhaler technique, perception of symptoms, and exposure to either allergens or viral infection. The relationship between changes in FENO measurements and asthma outcomes is less clear and requires further evaluation.

Acknowledgments

Author contributions: S. T. conceived the idea for the study, wrote the first draft of the manuscript, and is the guarantor of the study. S. T. and S. F. designed the study. All authors other than S. T. and S. F. contributed data for the analysis. S. F. undertook the analysis. All authors made contributions to the final manuscript.

Financial/nonfinancial disclosure: None declared.

Other contributions: The individual patient data analysis was carried out at the University of Aberdeen. Original data collection took place in the remaining institutions.

Additional information: The e-Appendix and e-Tables can be found in the Supplemental Materials section of the online article.

References

1. Asthma UK. Asthma facts and FAQs. 2017. <https://www.asthma.org.uk/about/media/facts-and-statistics/>. Accessed August 31, 2017.
2. Centers for Disease Control and Prevention. Asthma. Most recent data. 2016. https://www.cdc.gov/asthma/most_recent_data.htm. Accessed August 31, 2017.
3. Bacharier LB, Strunk RC, Mauer D, White D, Lemanske RFJ, Sorkness CA. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. *Am J Respir Crit Care Med*. 2004;170(4):426-432.
4. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. 2016 <https://www.brit-thoracic.org.uk/standards-of-care/guidelines/btssign-british-guideline-on-the-management-of-asthma/>. Accessed August 31, 2017.

5. Papadopoulos NG, Arakawa H, Carlsen K, et al. International consensus on (ICON) pediatric asthma. *Allergy*. 2012;67(8):976-997.
6. National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management. 2017. <https://www.nice.org.uk/guidance/ng80>. Accessed January 28, 2018.
7. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2017. <http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/>. Accessed August 31, 2017.
8. National Asthma Education and Prevention Program. Expert Panel Report 3—Guidelines for the Diagnosis and Management of Asthma. 2007. <https://www.nlm.nih.gov/files/docs/guidelines/asthsumm.pdf>. Accessed January 2, 2018.
9. Silkoff PE, Carlson M, Bourke T, Katial R, Ogren E, Szefer SJ. The Aerochrome exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. *J Allergy Clin Immunol*. 2004;114(5):1241-1256.
10. Dweik RA, Boggs PB, Erzurum SC, et al. American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med*. 2011;184(5):602-615.
11. Fritsch M, Uxa S, Horak FJ, et al. Exhaled nitric oxide in the management of childhood asthma: a prospective 6-months study. *Pediatr Pulmonol*. 2006;41(9):855-862.
12. Peirsman EJ, Carvelli TJ, Hage PY, et al. Exhaled nitric oxide in childhood allergic asthma management: a randomised controlled trial. *Pediatr Pulmonol*. 2014;49(7):624-631.
13. Petsky HL, Li AM, Au CT, Kynaston JA, Turner C, Chang AB. Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: a dual centre randomized controlled trial. *Pediatr Pulmonol*. 2015;50(6):535-543.
14. Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. *Am J Respir Crit Care Med*. 2005;172(7):831-836.
15. Pike K, Selby A, Price S, et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid dose in paediatric asthma: a randomised controlled trial. *Clin Respir J*. 2013;7(2):204-213.
16. Szefer SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. *Lancet*. 2008;372(9643):1065-1072.
17. Voorend-van Bergen S, Vaessen-Verberne AA, Brackel HJ, et al. Monitoring strategies in children with asthma: a randomised controlled trial. *Thorax*. 2015;70(6):543-550.
18. Turner S. Exhaled nitric oxide and the management of childhood asthma – yet another promising biomarker “has been” or a misunderstood gem. *Paediatr Respir Rev*. 2015;16(2):88-96.

19. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. *Brit Med J*. 2010;340:c221.
20. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J*. 2012;40(6):1324-1343.
21. Stanojevic S, Wade A, Stocks J, et al. Reference ranges for spirometry across all ages: a new approach. *Am J Respir Crit Care Med*. 2008;177(3):253-260.
22. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. *Brit Med J*. 2000;320(7244):1240-1243.
23. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. *Am J Respir Crit Care Med*. 2005;171(8):912-930.
24. Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. *Stat Med*. 2017;36(5):855-875.
25. Verini M, Consilvio NP, Di Pillo S, et al. FENO as a marker of airways inflammation: the possible implications in childhood asthma management. *J Allergy (Cairo)*. 2010. pii: 691425.
26. Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV(1) is associated with risk of asthma attacks in a pediatric population. *J Allergy Clin Immunol*. 2001;107(1):61-67.
27. Teach SJ, Gergen PJ, Szeffler SJ, et al. Seasonal risk factors for asthma exacerbations among inner-city children. *J Allergy Clin Immunol*. 2015;135(6):1465-1473.e5.
28. Wu AC, Tantisira K, Li L, et al. Predictors of symptoms are different from predictors of severe exacerbations from asthma in children. *Chest*. 2011;140(1):100-107.
29. Pijnenburg MW, Baraldi E, Brand PLP, et al. Monitoring asthma in children. *Eur Respir J*. 2015;45(4):906-925.